//Generics --> https://generics.citeline.com

Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From MedinCell SA

Teva Starts The Year With Phase III Data And Growth

Teva reported positive Phase III data for a long-acting version of olanzapine for schizophrenia, coinciding with its first quarter sales and earnings release.

Sales & Earnings Clinical Trials

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

Deal Watch Business Strategies

Teva Expects To Carve Out Sizable Niche For Uzedy In Antipsychotic Market

Uzedy was recently approved by the US FDA as an extended-release subcutaneous formula of risperidone; it is poised to be a new prong in Teva’s branded portfolio.

Launches Sales & Earnings

Teva Prepares To Launch LAI Risperidone After US Approval

Teva has indicated an imminent launch after gaining a long-awaited FDA approval for the Uzedy long-acting injectable risperidone 505(b)(2) hybrid product on which the firm has partnered with MedinCell. Pricing information has also been revealed.

Approvals Value-Added Medicines
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
UsernamePublicRestriction

Register